FibroGen, Inc. (0IL8.L)
USD 0.25
(-14.21%)
USD 0.25
(-14.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 56.76 Million USD | 186.25% |
| 2022 | -65.81 Million USD | 7.94% |
| 2021 | -71.48 Million USD | 88.84% |
| 2020 | -640.67 Million USD | -752.37% |
| 2019 | -75.16 Million USD | -1051.56% |
| 2018 | 7.89 Million USD | 101.37% |
| 2017 | -575.89 Million USD | -653.49% |
| 2016 | -76.43 Million USD | -35.8% |
| 2015 | -56.28 Million USD | 17.52% |
| 2014 | -68.23 Million USD | -433.22% |
| 2013 | 20.47 Million USD | -62.33% |
| 2012 | 54.35 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 23.06 Million USD | -63.31% |
| 2024 Q1 | 62.88 Million USD | 10.77% |
| 2023 Q2 | 3.64 Million USD | 103.58% |
| 2023 Q4 | 56.76 Million USD | 73.75% |
| 2023 FY | 56.76 Million USD | 186.25% |
| 2023 Q1 | -101.73 Million USD | -54.58% |
| 2023 Q3 | 32.67 Million USD | 795.83% |
| 2022 Q1 | -88.97 Million USD | -24.45% |
| 2022 FY | -65.81 Million USD | 7.94% |
| 2022 Q4 | -65.81 Million USD | -3.87% |
| 2022 Q3 | -63.36 Million USD | 14.02% |
| 2022 Q2 | -73.69 Million USD | 17.17% |
| 2021 Q4 | -71.48 Million USD | 58.48% |
| 2021 Q2 | -248.41 Million USD | 37.19% |
| 2021 Q3 | -172.19 Million USD | 30.68% |
| 2021 FY | -71.48 Million USD | 88.84% |
| 2021 Q1 | -395.48 Million USD | 38.27% |
| 2020 Q4 | -640.67 Million USD | -30.66% |
| 2020 Q1 | -73.57 Million USD | 2.11% |
| 2020 Q2 | -383.89 Million USD | -421.74% |
| 2020 Q3 | -490.33 Million USD | -27.73% |
| 2020 FY | -640.67 Million USD | -752.37% |
| 2019 FY | -75.16 Million USD | -1051.56% |
| 2019 Q4 | -75.16 Million USD | 47.25% |
| 2019 Q2 | -17.39 Million USD | 19.64% |
| 2019 Q1 | -21.64 Million USD | -374.03% |
| 2019 Q3 | -142.48 Million USD | -719.18% |
| 2018 Q1 | -561.38 Million USD | 2.52% |
| 2018 FY | 7.89 Million USD | 101.37% |
| 2018 Q4 | 7.89 Million USD | 101.68% |
| 2018 Q3 | -469.39 Million USD | 14.08% |
| 2018 Q2 | -546.33 Million USD | 2.68% |
| 2017 Q1 | -73.06 Million USD | 4.41% |
| 2017 FY | -575.89 Million USD | -653.49% |
| 2017 Q4 | -575.89 Million USD | -3.95% |
| 2017 Q3 | -554 Million USD | -187.31% |
| 2017 Q2 | -192.82 Million USD | -163.92% |
| 2016 Q1 | -43.88 Million USD | 22.03% |
| 2016 FY | -76.43 Million USD | -35.8% |
| 2016 Q4 | -76.43 Million USD | 24.26% |
| 2016 Q3 | -100.9 Million USD | -8.48% |
| 2016 Q2 | -93.01 Million USD | -111.97% |
| 2015 Q3 | -111.66 Million USD | 20.02% |
| 2015 Q1 | -31.49 Million USD | 53.84% |
| 2015 Q2 | -139.6 Million USD | -343.25% |
| 2015 FY | -56.28 Million USD | 17.52% |
| 2015 Q4 | -56.28 Million USD | 49.6% |
| 2014 Q4 | -68.23 Million USD | -19.89% |
| 2014 Q3 | -56.91 Million USD | 33.63% |
| 2014 Q2 | -85.74 Million USD | -304.95% |
| 2014 Q1 | 41.83 Million USD | 104.32% |
| 2014 FY | -68.23 Million USD | -433.22% |
| 2013 Q4 | 20.47 Million USD | 0.0% |
| 2013 Q1 | 39.88 Million USD | 0.0% |
| 2013 FY | 20.47 Million USD | -62.33% |
| 2012 FY | 54.35 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 155.14% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 281.846% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 71.339% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -78.037% |
| bluebird bio, Inc. | 108.57 Million USD | 47.714% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 729.625% |
| Imunon, Inc. | -4.69 Million USD | 1307.995% |
| Editas Medicine, Inc. | -87.11 Million USD | 165.163% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.558% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 97.294% |
| Myriad Genetics, Inc. | 88.1 Million USD | 35.565% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 67.983% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 269.317% |
| Verastem, Inc. | -37.27 Million USD | 252.28% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.311% |
| Waters Corporation | 1.96 Billion USD | 97.104% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.788% |
| Biogen Inc. | 6.28 Billion USD | 99.097% |
| Nektar Therapeutics | 210.24 Million USD | 72.999% |
| Perrigo Company plc | 3.32 Billion USD | 98.291% |
| Dynavax Technologies Corporation | 106.63 Million USD | 46.765% |
| Illumina, Inc. | 1.21 Billion USD | 95.324% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -714.673% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 149.845% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 60.871% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -689.857% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 85.012% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 899.535% |
| Evolus, Inc. | 63.7 Million USD | 10.895% |
| Adicet Bio, Inc. | -142 Million USD | 139.975% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 254.241% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 309.472% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 87.624% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 95.042% |
| OPKO Health, Inc. | 230.68 Million USD | 75.392% |
| Homology Medicines, Inc. | 18.43 Million USD | -207.897% |
| Geron Corporation | 14.76 Million USD | -284.574% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 96.419% |
| Exelixis, Inc. | -73.05 Million USD | 177.71% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 204.628% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 137.588% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 150.957% |
| Zoetis Inc. | 4.76 Billion USD | 98.808% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 128.409% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 663.668% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.594% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 489.562% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 94.616% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 94.138% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 141.925% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 95.889% |
| Blueprint Medicines Corporation | 702.83 Million USD | 91.923% |
| Insmed Incorporated | 721.62 Million USD | 92.133% |
| TG Therapeutics, Inc. | 17.86 Million USD | -217.809% |
| Incyte Corporation | -3.17 Billion USD | 101.788% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 92.587% |